BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, de Velasco G, Trinh QD, Choueiri TK. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol 2016;34:3267-75. [PMID: 27325852 DOI: 10.1200/JCO.2016.66.7931] [Cited by in Crossref: 118] [Cited by in F6Publishing: 44] [Article Influence: 19.7] [Reference Citation Analysis]
Number Citing Articles
1 Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open 2021;4:e2111329. [PMID: 34032854 DOI: 10.1001/jamanetworkopen.2021.11329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Gilbert N, Merseburger AS, Kramer MW. [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?]. Urologe A 2017;56:604-9. [PMID: 28314973 DOI: 10.1007/s00120-017-0364-x] [Reference Citation Analysis]
3 Gill DM, Agarwal N, Vaishampayan U. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book 2017;37:319-29. [PMID: 28561652 DOI: 10.1200/EDBK_174469] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
4 Karadurmuş N, Ertürk İ. Which is the best for cancer treatment? Surgery or chemotherapy. Journal of Oncological Sciences 2017;3:32-3. [DOI: 10.1016/j.jons.2017.02.001] [Reference Citation Analysis]
5 Graham J, Wells JC, Donskov F, Lee JL, Fraccon A, Pasini F, Porta C, Bowman IA, Bjarnason GA, Ernst DS, Rha SY, Beuselinck B, Hansen A, North SA, Kollmannsberger CK, Wood LA, Vaishampayan UN, Pal SK, Choueiri TK, Heng DYC. Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol 2019;2:643-8. [PMID: 31411994 DOI: 10.1016/j.euo.2019.03.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
6 Zumsteg ZS, Luu M, Yoshida EJ, Kim S, Tighiouart M, David JM, Shiao SL, Mita AC, Scher KS, Sherman EJ, Lee NY, Ho AS. Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. Cancer 2017;123:4583-93. [PMID: 28817183 DOI: 10.1002/cncr.30933] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
7 Vaishampayan U. Landmark Trials in Renal Cancer. KCA 2018;2:11-21. [DOI: 10.3233/kca-170026] [Reference Citation Analysis]
8 Gu CY, Wang JJ, Zhang HL, Shi GH, Ye DW. Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation. Front Oncol 2021;11:762547. [PMID: 34746004 DOI: 10.3389/fonc.2021.762547] [Reference Citation Analysis]
9 Buttigliero C, Tucci M, Vignani F, Di Maio M. Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias? J Clin Oncol 2017;35:1264. [PMID: 28165894 DOI: 10.1200/JCO.2016.69.3580] [Reference Citation Analysis]
10 Chakiryan NH, Gore LR, Reich RR, Dunn RL, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Manley BJ, Sexton WJ, Hollenbeck BK, Gilbert SM. Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open 2022;5:e2212347. [PMID: 35576003 DOI: 10.1001/jamanetworkopen.2022.12347] [Reference Citation Analysis]
11 Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, Shinohara N. Overview of clinical management for older patients with renal cell carcinoma. Jpn J Clin Oncol 2022:hyac047. [PMID: 35397166 DOI: 10.1093/jjco/hyac047] [Reference Citation Analysis]
12 Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can Urol Assoc J 2019;13:166-74. [PMID: 31199235 DOI: 10.5489/cuaj.5786] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Chen T, Zhan X, Du J, Liu X, Deng W, Zhao S, Jiang M, Xiong Y, Zhang X, Chen L, Fu B. A Simple-To-Use Nomogram for Predicting Early Death in Metastatic Renal Cell Carcinoma: A Population-Based Study. Front Surg 2022;9:871577. [DOI: 10.3389/fsurg.2022.871577] [Reference Citation Analysis]
14 Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol 2020;10:627025. [PMID: 33643921 DOI: 10.3389/fonc.2020.627025] [Reference Citation Analysis]
15 Shinder BM, Rhee K, Farrell D, Farber NJ, Stein MN, Jang TL, Singer EA. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol. 2017;7:107. [PMID: 28620578 DOI: 10.3389/fonc.2017.00107] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
16 Renner A, Samtani S, Marín A, Burotto M. Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma? J Kidney Cancer VHL 2019;6:1-7. [PMID: 30881867 DOI: 10.15586/jkcvhl.2019.114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 De Maeseneer DJ, Delafontaine B, Rottey S. Checkpoint inhibition: new treatment options in urologic cancer. Acta Clin Belg 2017;72:24-8. [PMID: 28151378 DOI: 10.1080/17843286.2016.1260890] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
18 Vaishampayan U, George J, Vigneau F. Predictors of Cytoreductive Nephrectomy for Metastatic Kidney Cancer in SEER and Metropolitan Detroit Databases. J Kidney Cancer VHL 2019;6:13-25. [PMID: 31750074 DOI: 10.15586/jkcvhl.2019.121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Singla N, Hutchinson RC, Ghandour RA, Freifeld Y, Fang D, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. Urol Oncol 2020;38:604.e9-604.e17. [PMID: 32253116 DOI: 10.1016/j.urolonc.2020.02.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
20 Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Curr Oncol Rep 2020;22:35. [PMID: 32170461 DOI: 10.1007/s11912-020-0895-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Oronsky B, Larson C, Reid TR, Carter CA. Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer. J Investig Med High Impact Case Rep 2018;6:2324709618786319. [PMID: 30083560 DOI: 10.1177/2324709618786319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Kamarajah SK, Nathan H. Strengths and Limitations of Registries in Surgical Oncology Research. J Gastrointest Surg 2021. [PMID: 34506025 DOI: 10.1007/s11605-021-05094-y] [Reference Citation Analysis]
23 Correa RJM, Ahmad B, Warner A, Johnson C, MacKenzie MJ, Pautler SE, Bauman GS, Rodrigues GB, Louie AV. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma. Radiat Oncol 2018;13:47. [PMID: 29558966 DOI: 10.1186/s13014-018-0992-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
24 Kim SH, Kim JK, Park B, Joo J, Joung JY, Seo HK, Lee KH, Chung J. Effect of renal embolization in patients with synchronous metastatic renal cell carcinoma: a retrospective comparison of cytoreductive nephrectomy and systemic medical therapy. Oncotarget 2017;8:49615-24. [PMID: 28548948 DOI: 10.18632/oncotarget.17865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Rudra S, Fischer-Valuck B, Pachynski R, Daly M, Green O. Magnetic Resonance Image Guided Stereotactic Body Radiation Therapy to the Primary Renal Mass in Metastatic Renal Cell Carcinoma. Adv Radiat Oncol 2019;4:566-70. [PMID: 31673649 DOI: 10.1016/j.adro.2019.04.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
26 Anderson B, Williams GA, Sanford DE, Liu J, Dageforde LA, Hammill CW, Fields RC, Hawkins WG, Strasberg SM, Doyle MB, Chapman WC, Khan AS. A 22-year experience with pancreatic resection for metastatic renal cell carcinoma. HPB (Oxford). 2020;22:312-317. [PMID: 31345661 DOI: 10.1016/j.hpb.2019.05.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
27 Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer 2018;94:115-25. [PMID: 29550566 DOI: 10.1016/j.ejca.2018.02.012] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 34.8] [Reference Citation Analysis]
28 Kalapara AA, Frydenberg M. The role of open radical nephrectomy in contemporary management of renal cell carcinoma. Transl Androl Urol 2020;9:3123-39. [PMID: 33457285 DOI: 10.21037/tau-19-327] [Reference Citation Analysis]
29 Beltagy A, Ismail A, Elmansy H, Shahrour W, Prowse O, Kotb A. Sunitinib cause delayed complete response on metastatic RCC and extensive IVC thrombus, but not to the kidney tumor: a case report and review of literature. J Surg Case Rep 2019;2019:rjz326. [PMID: 31737248 DOI: 10.1093/jscr/rjz326] [Reference Citation Analysis]
30 Faba OR, Brookman-May SD, Linares E, Breda A, Pisano F, Subiela JD, Sanguedolce F, Brausi M, Palou J. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review. World J Urol 2017;35:1807-16. [PMID: 28702843 DOI: 10.1007/s00345-017-2072-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
31 Chandrasekar T, Klaassen Z, Goldberg H, Sayyid RK, Kulkarni GS, Fleshner NE. High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. Oncotarget 2018;9:16731-43. [PMID: 29682181 DOI: 10.18632/oncotarget.24675] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
32 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
33 Zheng W, Zhu W, Yu S, Li K, Ding Y, Wu Q, Tang Q, Zhao Q, Lu C, Guo C. Development and validation of a nomogram to predict overall survival for patients with metastatic renal cell carcinoma. BMC Cancer 2020;20:1066. [PMID: 33148204 DOI: 10.1186/s12885-020-07586-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Carvalho FLF, Zheng C, Witmer K, O'neill J, Lynch JH, Kowalczyk KJ. Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy. Sci Rep 2019;9:15272. [PMID: 31649310 DOI: 10.1038/s41598-019-51548-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Donskov F, Motzer RJ, Voog E, Hovey E, Grüllich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2020;126:1-10. [PMID: 31887537 DOI: 10.1016/j.ejca.2019.10.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
36 Klatte T, Fife K, Welsh SJ, Sachdeva M, Armitage JN, 'Aho T, Riddick AC, Matakidou A, Eisen T, Stewart GD. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting. World J Urol 2018;36:417-25. [PMID: 29256020 DOI: 10.1007/s00345-017-2154-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
37 Poprach A, Holanek M, Chloupkova R, Lakomy R, Stanik M, Fiala O, Melichar B, Kopeckova K, Zemanova M, Kiss I, Penka I, Bohosova J, Buchler T. Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy-Data from the National Renis Registry. Cancers (Basel) 2020;12:E2911. [PMID: 33050532 DOI: 10.3390/cancers12102911] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hall ME, Bhindi B, Luckenbaugh AN, Laviana AA, Moses KA, Satkunasivam R, Rini B, Klaassen Z, Wallis CJD. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. Cancer Causes Control 2021;32:675-80. [PMID: 33963938 DOI: 10.1007/s10552-021-01435-z] [Reference Citation Analysis]
39 Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood L, van Melick HHE, Aarts MJ, Lattouf JB, Powles T, de Jong Md PhD IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen J. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncol 2019;5:164-70. [PMID: 30543350 DOI: 10.1001/jamaoncol.2018.5543] [Cited by in Crossref: 132] [Cited by in F6Publishing: 147] [Article Influence: 44.0] [Reference Citation Analysis]
40 Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. [PMID: 28276433 DOI: 10.1038/nrdp.2017.9] [Cited by in Crossref: 616] [Cited by in F6Publishing: 675] [Article Influence: 123.2] [Reference Citation Analysis]
41 McCormick B, Meissner MA, Karam JA, Wood CG. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer 2017;1:115-21. [PMID: 30334013 DOI: 10.3233/KCA-170016] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Sun M, Hanna N, Trinh QD, Choueiri TK. Reply to C. Buttigliero et al and B. Biswas et al. J Clin Oncol 2017;35:1266-7. [PMID: 28165905 DOI: 10.1200/JCO.2016.71.7249] [Reference Citation Analysis]
43 Berghen C, Joniau S, Vulsteke C, Albersen M, Devos G, Rans K, Haustermans K, De Meerleer G. Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news. Ecancermedicalscience 2020;14:1036. [PMID: 32565889 DOI: 10.3332/ecancer.2020.1036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Sidaway P. Kidney cancer: Cytoreductive nephrectomy improves outcomes in the era of targeted therapy. Nat Rev Urol 2016;13:438. [PMID: 27377158 DOI: 10.1038/nrurol.2016.127] [Reference Citation Analysis]
45 Patel MI, Beattie K, Bang A, Gurney H, Smith DP. Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival. Cancer Med 2017;6:2188-93. [PMID: 28834281 DOI: 10.1002/cam4.1137] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
46 Zhao K, Kim EH, Vetter JM, Hsieh JJ, Venkatesh R, Bhayani SB, Figenshau RS. Laparoscopic cytoreductive nephrectomy is associated with significantly improved survival compared with open cytoreductive nephrectomy or targeted therapy alone. Mol Clin Oncol 2020;13:71. [PMID: 33005405 DOI: 10.3892/mco.2020.2141] [Reference Citation Analysis]
47 Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. Int Urol Nephrol 2019;51:2181-8. [PMID: 31468289 DOI: 10.1007/s11255-019-02266-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
48 Siva S, Kothari G, Muacevic A, Louie AV, Slotman BJ, Teh BS, Lo SS. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nat Rev Urol 2017;14:549-63. [PMID: 28631740 DOI: 10.1038/nrurol.2017.87] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 8.4] [Reference Citation Analysis]
49 Xu WH, Wang J, Huo DZ, Yin GC, Cao DL, Shi GH, Qu YY, Ye DW, Zhang HL. C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study. Med Sci Monit 2019;25:8984-94. [PMID: 31769434 DOI: 10.12659/MSM.918635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Batai K, Harb-De la Rosa A, Zeng J, Chipollini JJ, Gachupin FC, Lee BR. Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes. Cancer Med 2019;8:6780-8. [PMID: 31509346 DOI: 10.1002/cam4.2552] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
51 Tannir NM, Powles T, Escudier B, Donskov F, Grünwald V, Sternberg CN, Schmidinger M, Schöffski P, Szczylik C, Peltolta K, Nosov D, Melichar B, Clary D, Scheffold C, Motzer RJ, Choueiri TK. Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. KCA 2020;4:29-39. [DOI: 10.3233/kca-190080] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Brozzetti S, Bini S, De Lio N, Lombardo C, Boggi U. Surgical-only treatment of pancreatic and extra-pancreatic metastases from renal cell carcinoma - quality of life and survival analysis. BMC Surg 2020;20:101. [PMID: 32404091 DOI: 10.1186/s12893-020-00757-0] [Reference Citation Analysis]
53 Tabakin AL, Stein MN, Anderson CB, Drake CG, Singer EA. Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic 'Choosing Wisely' campaign: a narrative review. Transl Cancer Res 2020;9:7337-49. [PMID: 33354523 DOI: 10.21037/tcr-20-2343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A. A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors. Lung Cancer (Auckl) 2019;10:95-105. [PMID: 31572037 DOI: 10.2147/LCTT.S219886] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Dursun F, Ramamurthy C, Kaushik D. "Immune-Cell Pawns" Plot Promotion and Corner Kidney Cancer: CheckMate 214. Eur Urol 2021:S0302-2838(21)02148-5. [PMID: 34838352 DOI: 10.1016/j.eururo.2021.11.006] [Reference Citation Analysis]
56 Dilme RV, Rivas JG, Campi R, Puente J, Jerez T, Enikeev D, Esperto F, Sierra JM. Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: Is There Still a Debate? Curr Urol Rep 2021;22:54. [PMID: 34654989 DOI: 10.1007/s11934-021-01073-7] [Reference Citation Analysis]